



March 31, 2017

## **Spectrum Pharmaceuticals Highlights Three Abstracts on ROLONTIS™ (eflapegrastim) and BELEODAQ® (belinostat) for injection at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C., April 1-5, 2017**

HENDERSON, Nev.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced key presentations of clinical and scientific data related to its products at the American Association for Cancer Research (AACR) Annual Meeting being held in Washington, D.C., from April 1-5, 2017.

**The following ROLONTIS™ (eflapegrastim) related abstract is being presented at the AACR meeting:**

*Monday, April 3, 2017:*

<b>Abstract #</b>	<b>Type</b>	<b>Title</b>	<b>First Author</b>	<b>Time</b>
1347	Poster	In vivo efficacy of eflapegrastim in rats with chemotherapy-induced neutropenia	Kim	8:00 AM -12:00 PM

**The following key BELEODAQ® (belinostat) for injection related abstracts are being presented at the AACR meeting:**

*Monday, April 3, 2017:*

<b>Abstract #</b>	<b>Type</b>	<b>Title</b>	<b>First Author</b>	<b>Time</b>
1059	Poster	Enhanced anti-tumor efficacy of a checkpoint inhibitor in combination with the HDAC inhibitor belinostat in a murine hepatocellular carcinoma preclinical model	Llopiz	8:00 AM-12:00 PM
2018	Poster	Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms	Nguyen	1:00 PM-5:00 PM

For more information about the AACR meeting and for a complete list of abstracts, please refer to the conference website at <http://www.abstractsonline.com/pp8/#/4292>.

### **About Spectrum Pharmaceuticals, Inc.**

Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in Hematology and Oncology. Spectrum currently markets six hematology/oncology drugs, and has an advanced stage pipeline that has the potential to transform the Company. Spectrum's strong track record for in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. More information on Spectrum is available at [www.sppirx.com](http://www.sppirx.com).

*Forward-looking statement - This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include, but are not limited to, statements that relate to Spectrum's business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, the timing and results of FDA decisions, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual*

*results to differ include the possibility that Spectrum's existing and new drug candidates may not prove safe or effective, the possibility that our existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.*

*SPECTRUM PHARMACEUTICALS, INC. and BELEODAQ® are registered trademarks of Spectrum Pharmaceuticals, Inc. and its affiliates. REDEFINING CANCER CARE™, and ROLONTIS™ and the Spectrum Pharmaceuticals' logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.*

© 2017 Spectrum Pharmaceuticals, Inc. All Rights Reserved.

View source version on [businesswire.com](http://www.businesswire.com/news/home/20170331005077/en/): <http://www.businesswire.com/news/home/20170331005077/en/>

Spectrum Pharmaceuticals, Inc.  
Shiv Kapoor, 702-835-6300  
Vice President, Strategic Planning & Investor Relations  
[InvestorRelations@sppirx.com](mailto:InvestorRelations@sppirx.com)

Source: Spectrum Pharmaceuticals, Inc.

News Provided by Acquire Media